Danusertib

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameDanusertib
Drug Alias NameDanusertibum达努舍替达那色替NMS Aurora inhibitor达鲁舍替 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora-A inhibitorsSerine/threonine-protein kinase Aurora-C inhibitorsSerine/threonine-protein kinase Aurora-B inhibitors
TargetsSerine/threonine-protein kinase Aurora-ASerine/threonine-protein kinase Aurora-CSerine/threonine-protein kinase Aurora-B
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsMultiple MyelomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNerviano Medical Sciences Srl
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteNerviano Medical Sciences Srl
Active IndicationsN/A
Inactive IndicationsHormone-Resistant Prostate NeoplasmsMultiple MyelomaLeukemia

Other Information

ATC CodeN/A
Related LinksN/A